Company: RGNT
Filing Date: 2025-07-07
Form Type: F-1/A
Source: 0001213900-25-061821
Chunk: 101

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-07-07
Form: F-1/A
Chunk 101
---
 the average price paid per share by existing shareholders and by new investors purchasing Ordinary Shares in this offering
at an assumed initial public offering price of $11.00 per Ordinary Share, which is the midpoint of the price range set forth on the cover
page of this prospectus, before deducting the estimated underwriting discounts and commissions and estimated offering expenses payable
by us:

|                       |     | Shares 
 Number |           |     | Percent |       |   |     | Total Consideration 
 Amount              |            |     | Percent |       |   |     | Average Price 
 Per Ordinary  
 Share         |      |
|:----------------------|:----|:-------|----------:|:----|:--------|------:|:--|:----|:--------------------|-----------:|:----|:--------|------:|:--|:----|:--------------|-----:|
| Existing shareholders |     |        | 3,929,378 |     |         |  79.7 | % |     | $                   | 36,197,100 |     |         |  76.7 | % |     | $             | 9.21 |
| New investors         |     |        | 1,000,000 |     |         |  20.3 | % |     | $                   | 11,000,000 |     |         |  23.3 | % |     | $             | 11.0 |
| Total                 |     |        | 4,929,378 |     |         | 100.0 | % |     |                     | 47,197,100 |     | $       | 100.0 | % |     | $             | 9.57 |

A $0.25 increase (decrease)
in the assumed initial public offering price of $11.00 per Ordinary Share (the midpoint of the price range set forth on the cover
page of this prospectus) would increase (decrease) the total consideration paid by investors participating in this offering, total consideration
paid by all shareholders and the average price per share paid by all shareholders by approximately $0.23 million, assuming that the number
of Ordinary Shares offered by us, as set forth on the cover page of this prospectus, remains the same and before deducting the estimated
underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, a 100,000 share increase (decrease)
in the